Email This Article

FDA Grants QIDP Designation to Two Cubist Phase 3 Antibiotic Candidates
Cubist Pharmaceuticals, Inc. announces that the Food and Drug Administration (FDA) has designated two of the company’s Phase 3 antibiotic candidates, CXA-201 (ceftolozane/tazobactam) and CB-315, as Qualified Infectious Disease Products (QIDP). The QIDP designations will enable Cubist to benefit
To (required; use comma between emails, max Three):
 
Subject (required):
 
Your email address (required):
 
Message:
The message area is limited to 500 characters and allows for no html, URLs, email addresses or attachments.